Skip to main content
Clinical Trials/NCT00691886
NCT00691886
Withdrawn
Phase 4

Safety and Efficacy of Intravenous Dexmedetomidine Infusion During Flexible Bronchoscoy and Endobronchical Ultrasound

Lahey Clinic1 site in 1 countryApril 2008

Overview

Phase
Phase 4
Intervention
dexmedetomidine hydrochloride
Conditions
Pain
Sponsor
Lahey Clinic
Locations
1
Primary Endpoint
Achieve safe, consistent, continous moderate sedation using Dexmedetomidine in advanced bronchoscopy procedures, alleviating the need for rapid sedative infusion.
Status
Withdrawn
Last Updated
13 years ago

Overview

Brief Summary

To achieve safe,consistent, continuous sedation using Dexmedetomidine in advaced bronchoscopy procedures that may reduce the need for rapid pain sedative infusion.

Detailed Description

Dexmedetomidine hydrochloride as a single agent produces sedation, pain relief, anxiety redution, stable respiratory rates, and predictable cardiovascular responses. Dexmedetomidine facilitates patient comfort, compliance and comprehension by offering sedation with the ability to awaken patients. This study is being done to determine sedation efficacy and dosing; measure reduction or eliminate the need for rapid sedative infusion during bronchoscopy; improvement of patient comfort and safety during complex bronchoscopy; establish a new paradigm for moderate sedation during flexible bronchoscopy

Registry
clinicaltrials.gov
Start Date
April 2008
End Date
July 2012
Last Updated
13 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adults between the age of 18 and 85
  • Adults scheduled for flexible brochoscopy using EUBS (Endobronchial Ultrasound)

Exclusion Criteria

  • Sever bradycardia (rate \< 50) and / or related bradydysrhymias (e.g. advanced heart block)
  • Impaired ventricular functions (EF \<30%)
  • Hypovolemia or hypotension (SBP \<90 or MAP \<a55)
  • Have GFR less than 15ml/min 1.73m2 or undergoing hemodialysis
  • Endstage liver disease.

Arms & Interventions

2

Subjects undergoing EBUS randomized to arm 2 of the study will recieve demedetomadine hydrochloride plus standard of care conscious sedation

Intervention: dexmedetomidine hydrochloride

Outcomes

Primary Outcomes

Achieve safe, consistent, continous moderate sedation using Dexmedetomidine in advanced bronchoscopy procedures, alleviating the need for rapid sedative infusion.

Time Frame: at conclusion of subject enrollemtn

Study Sites (1)

Loading locations...

Similar Trials